Loading patent…
AssigneesThe United States of America, AS Represented By the Secretary, Department of He, Codagenix Inc.
InventorsCyril LE NOUEN, Ursula J. BUCHHOLZ, Peter L. COLLINS, Steffen MUELLER
Estimating the term…
Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K) L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
An isolated polynucleotide molecule encoding a recombinant respiratory syncytial virus (RSV) variant having an attenuated phenotype comprising a RSV genome or antigenome sequence, wherein the RSV genome or antigenome is modified by a mutation in the L ORF at a position correspond to T1166 of the L protein in SEQ ID NO:
A method of vaccinating a subject against RSV comprising administering the pharmaceutical composition of claim 17.
An isolated polynucleotide molecule encoding a recombinant respiratory syncytial virus (RSV) variant having an attenuated phenotype comprising a RSV genome or antigenome sequence, wherein the RSV genome or antigenome is modified by one or more mutations selected from the positions recited in Tables, S1.
An isolated polynucleotide molecule that is at least about 80% identical to the nucleotide sequence of SEQ ID NO:
Dependencies are inferred from the claim text.